Pulmonology

Approval of the novel long-acting mAb was based on the phase 3 SWIFT-1 and SWIFT-2 trials, which showed steep reductions in annualized asthma exacerbations requiring ED or inpatient care.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Phase 2b findings show rezpegaldesleukin reduced ACQ-5 scores and improved key AD endpoints in participants with comorbid asthma.

New longitudinal data from a Korean cohort suggest OSA may be an independent risk factor for cerebral small vessel disease.

WAYFINDER: 90% of steroid-dependent severe asthma patients reduced to ≤5mg daily on tezepelumab. Well-controlled asthma increased from 3% to 27% at 52 weeks.

Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.

Step-by-step treatment protocol for upper airway cough syndrome including nasal steroids, antihistamines, and proper administration technique.

Telemedicine follow-up after hospital discharge for COPD exacerbation was significantly more effective than standard care and received high patient satisfaction scores.

Approval of the novel oral PDE4B inhibitor offers hope to individuals with the rare, chronic, and progressive pulmonary disease for which treatment options are few.